We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

39 hedge funds and large institutions have $37.4M invested in Cue Biopharma in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,000% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 1

280% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 5

44% more capital invested

Capital invested by funds: $25.9M → $37.4M (+$11.4M)

34% more funds holding

Funds holding: 29 → 39 (+10)

0.21% more ownership

Funds ownership: 0.32% → 0.52% (+0.21%)

Holders
39
Holders Change
+10
Holders Change %
+34.48%
% of All Funds
0.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
19
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.46M
2
NCM
Nantahala Capital Management
Connecticut
+$5.61M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$2.87M
4
Northern Trust
Northern Trust
Illinois
+$1.4M
5
State Street
State Street
Massachusetts
+$1.32M

Top Sellers

Rank Fund Capital Flow
1
First Eagle Investment Management
First Eagle Investment Management
New York
-$4.04M
2
Citigroup
Citigroup
New York
-$458K
3
VF
Virtu Financial
New York
-$232K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$15.1K
5
Barclays
Barclays
United Kingdom
-$7.16K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$10.5M +$6.46M +16,238 +123%
Vanguard Group
2
Vanguard Group
Pennsylvania
$7.93M +$2.87M +7,216 +48%
NCM
3
Nantahala Capital Management
Connecticut
$5.02M +$5.61M +14,119 New
State Street
4
State Street
Massachusetts
$2.58M +$1.32M +3,314 +84%
First Eagle Investment Management
5
First Eagle Investment Management
New York
$2.31M -$4.04M -10,167 -61%
Northern Trust
6
Northern Trust
Illinois
$2.14M +$1.4M +3,511 +140%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$1.3M +$510K +1,283 +54%
Bank of New York Mellon
8
Bank of New York Mellon
New York
$527K +$295K +741 +100%
Morgan Stanley
9
Morgan Stanley
New York
$484K +$232K +583 +75%
TCIM
10
TIAA CREF Investment Management
New York
$460K +$514K +1,293 New
Deutsche Bank
11
Deutsche Bank
Germany
$402K +$297K +748 +196%
Charles Schwab
12
Charles Schwab
California
$393K +$223K +560 +103%
PAWC
13
P.A.W. Capital
Connecticut
$356K – – –
California State Teachers Retirement System (CalSTRS)
14
California State Teachers Retirement System (CalSTRS)
California
$321K +$179K +450 +100%
UBS Group
15
UBS Group
Switzerland
$275K +$258K +649 +528%
TA
16
Teachers Advisors
New York
$263K +$153K +385 +109%
Citigroup
17
Citigroup
New York
$255K -$458K -1,152 -62%
WP
18
WealthSource Partners
California
$246K +$275K +692 New
New York State Common Retirement Fund
19
New York State Common Retirement Fund
New York
$234K +$261K +657 New
Wells Fargo
20
Wells Fargo
California
$231K +$191K +480 +282%
RhumbLine Advisers
21
RhumbLine Advisers
Massachusetts
$188K +$210K +529 New
Manulife (Manufacturers Life Insurance)
22
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$179K +$99K +249 +97%
SCP
23
Silverleafe Capital Partners
Tennessee
$166K +$186K +467 New
Goldman Sachs
24
Goldman Sachs
New York
$147K +$164K +413 New
AIG
25
American International Group
New York
$137K +$77.1K +194 +102%
1
2

CUE Hedge Fund Activity: Q2 2018 in Review

39 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2018, worth a combined $37.4M — up 44% from $25.9M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new CUE positions and 1 closed out — a net gain of 10 holders — while 19 added to existing stakes and 5 trimmed.

The largest buyer was BlackRock, adding an estimated $6.46M. The largest seller was First Eagle Investment Management, cutting an estimated $4.04M.

  • 39 institutional investors held Cue Biopharma (CUE) as of Q2 2018, up from 29 in Q1 2018.
  • Funds reported $37.4M of Cue Biopharma stock for Q2 2018, up 44% quarter-over-quarter.
  • 11 funds opened new Cue Biopharma positions in Q2 2018 and 1 closed out, a net change of +10 holders.
  • The largest Cue Biopharma buyer in Q2 2018 was BlackRock, an estimated $6.46M added.
  • The largest Cue Biopharma seller in Q2 2018 was First Eagle Investment Management, an estimated $4.04M sold.

Based on aggregated 13F filings for Q2 2018.